1-(β-D-xylofuranosyl)-5-fluorocytosine | 669055-50-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-(β-D-xylofuranosyl)-5-fluorocytosine
• 英文别名: 5-Fluorcytidin；4-amino-1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoropyrimidin-2-one
• CAS: 669055-50-9
• 化学式: C₉H₁₂FN₃O₅
• 分子量: 261.21
• InChiKey: STRZQWQNZQMHQR-BYPJNBLXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.42
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  130.83
• 氢给体数：
  4.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  1-(β-D-xylofuranosyl)-5-fluorocytosine 在 氯化亚砜 、 碳酸氢钠 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 5-氟胞嘧啶核苷
  参考文献：
  名称：

  一种新的保护基团“3 ' ，5 ' - ø -亚磺酰基”为木糖核苷。一种简单的3高效合成' -氨基-3 '脱氧腺苷（嘌呤霉素中间），2,2- ' -anhydro嘧啶核苷和2 '，3 ' -anhydro腺苷

  摘要：

  我们开发了一种新的保护基团，为保护3的循环亚'，5 '核苷的二羟基组。分别由相应的木尿苷1和2以及木苷腺苷3和亚硫酰氯分别高产率地制备了七个环状亚硫酸盐4a – c，5a – b和6a – b。嘌呤霉素中间体的合成8是由亚硫酸盐部分的脱保护通过2的分子内环化进行' -α -氨基甲酸酯7。

  DOI：

  10.1016/j.tetlet.2003.10.092

文献信息

• A simple and efficient synthesis of puromycin, 2,2′-anhydro-pyrimidine nucleosides, cytidines and 2′,3′-anhydroadenosine from 3′,5′-<i>O</i>-sulfinyl<i>Xylo</i>-nucleosides
  作者：Ken-ichi Takatsuki、Sumito Ohgushi、Shigeo Kohmoto、Keiki Kishikawa、Makoto Yamamoto

  DOI：10.1080/15257770600725929

  日期：2006.8

  antibiotics, puromycin and 3 ′-amino-3 ′-deoxy-N 6,N 6-dimethyladenosine 11 was achieved by utilizing the cyclic sulfite 6a of the xylo-3 ′,5 ′-dihydroxy group as a new protective group. The key synthetic step is the deprotection of the sulfite moiety through the intramolecular cyclization of 2-α-carbamate 7. In a similar manner, 2,2 ′-anhydro-pyrimidine nucleosides 15, ribo-cytidines 17 and 2 ′,3 ′-anhydroadenosine

  利用xylo-3′，5′-二羟基的环状亚硫酸盐6a作为新的保护基，合成了嘌呤霉素和3′-氨基-3′-脱氧-N 6，N 6-二甲基腺苷11。关键的合成步骤是通过2-α-氨基甲酸酯7的分子内环化作用对亚硫酸盐部分进行脱保护。类似地，2,2'-脱水嘧啶核苷15，核糖胞苷17和2'，3'-分别由相应的亚硫酸盐4、5和6b高产率地制备了脱水腺苷14。
• Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
  申请人：——

  公开号：US20030087873A1

  公开（公告）日：2003-05-08

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  该公开的发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖有关的病况的组合物和方法，适用于宿主，包括动物，尤其是人类，使用通用式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。该发明还提供了一种有效的过程，用于量化病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，使用实时聚合酶链反应（RT-PCR）。此外，该发明揭示了可以与样本中存在的病毒数量成比例发光的探针分子。
• Nucleosides for imaging and treatment applications
  申请人：The Government of the United States of America, Secretary of Health and Human Services

  公开号：US20020022001A1

  公开（公告）日：2002-02-21

  Methods of diagnosing and/or of treating tumors by administering a nucleoside analogue which is activated by thymidylate synthase and/or thymidine kinase enzyme into a diagnostic or toxic metabolite, and uridine analogue compounds, and compositions of same having a pharmaceutically acceptable carrier. For diagnostic applications, compounds containing a label and methods of use of such compounds are described.

  通过向患者施用由胸腺嘧啶酸合成酶和/或胸腺嘧啶激酶酶激活的核苷类似物，使其转化为诊断或毒性代谢产物，以及尿嘧啶类似物化合物，以及具有药学可接受载体的组合物，来诊断和/或治疗肿瘤的方法。对于诊断应用，描述了含有标签的化合物以及使用这些化合物的方法。
• Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation
  申请人：Stuyver Lieven

  公开号：US20110269707A1

  公开（公告）日：2011-11-03

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用通式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了探针分子，可以与样品中存在的病毒数量成比例地发出荧光。
• MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD SCIENCES, INC.

  公开号：US20140057863A1

  公开（公告）日：2014-02-27

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感病毒）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用一种核苷酸的一般式（I）-（XXIII）或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或West Nile病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了可以与样品中存在的病毒数量成比例发光的探针分子。